The Kwan Lion Dance Team has been performing in Cleveland area restaurants and rec centers for Lunar New Year for decades.

Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck KGaA (XTRA:MRK) has ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its effort to diversify ahead of patent loss for its blockbuster cancer drug ...

Merck (MRK) on Tuesday announced an agreement under which funds managed by Blackstone (BX) Life Sciences will provide the New Jersey-based pharma giant with $700M to advance a cancer therapy called ...

Merck on Monday announced the groundbreaking of its new Virginia pharmaceutical manufacturing facility, a cornerstone of the company’s $70 billion U.S. investment strategy. The 400,000-square-foot ...

Merck & Co. will build a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to create 500 jobs, Gov. Glenn Youngkin and the company announced at a ceremonial groundbreaking ...

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multiyear effort comes as Merck prepares to ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio. With the stock valued at only 12 times ...